Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
about
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.New complex chromosome abnormalities in multiple myeloma associated with a poor prognosis: a case report.Defining and treating high-risk multiple myeloma.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.Stable renal engraftment in a patient following successful tandem autologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del(17p) that developed as a post-transplantation lymphoproliferative diseaAdverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.
P2860
Q36031316-972D226E-30A2-4F32-ACB7-4BB550382D5FQ36834629-7965CF7A-3E54-46E8-A28B-E3BB32F8B69AQ37037265-C06269AD-DC3C-4C76-84AB-22B72D2A1316Q37592526-BCB6BB95-9177-4D06-99FA-83AEB495686EQ38564926-7ECAE1D8-1F4A-455B-AE05-655C9595A754Q38979403-E3CBDDFD-8641-4856-A180-5414B190A02BQ39174731-BE7E4EE5-ECD2-48BF-8313-BE90FC313A8CQ41031177-EB39B61E-9D59-4EDD-B915-81FA12BBF40CQ43146952-E955EC81-90FB-4B13-B7D5-FA9C5F6A545CQ47794767-71B7A099-CEEC-47DD-B7C5-1DD422A06A5FQ50036381-A04E6972-C596-48B5-A35E-078C015BB2A9Q50491205-F58A9868-291F-42D3-A101-ECDA4202B1F5Q52699611-4E1D440B-13CE-4F68-ACD8-6BF4E5576DFBQ55026920-8584BA03-1484-4A20-A800-B80AB24B6E8D
P2860
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of genetic abnormalitie ...... lle et de Thérapie Cellulaire.
@ast
Impact of genetic abnormalitie ...... lle et de Thérapie Cellulaire.
@en
type
label
Impact of genetic abnormalitie ...... lle et de Thérapie Cellulaire.
@ast
Impact of genetic abnormalitie ...... lle et de Thérapie Cellulaire.
@en
prefLabel
Impact of genetic abnormalitie ...... lle et de Thérapie Cellulaire.
@ast
Impact of genetic abnormalitie ...... lle et de Thérapie Cellulaire.
@en
P2093
P2860
P50
P1433
P1476
Impact of genetic abnormalitie ...... lle et de Thérapie Cellulaire.
@en
P2093
Anne Thiebaut
Didier Blaise
Jean Soulier
Jean-Louis Golmard
Jean-Paul Fermand
Mathieu Kuentz
Mauricette Michallet
Natacha Maillard
Nathalie Dhédin
Nicole Raus
P2860
P304
P356
10.3324/HAEMATOL.2011.042713
P577
2011-06-17T00:00:00Z